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Abstract
Background: Gene profiling studies provide important information for key molecules relevant to a disease but are less
informative of protein-protein interactions, post-translational modifications and regulation by targeted subcellular
localization. Integration of genomic data and construction of functional gene networks may provide additional insights into
complex diseases such as systemic lupus erythematosus (SLE).
Methodology/Principal Findings: We analyzed gene expression microarray data of bone marrow mononuclear cells
(BMMCs) from 20 SLE patients (11 with active disease) and 10 controls. Gene networks were constructed using the
bioinformatic tool Ingenuity Gene Network Analysis. In SLE patients, comparative analysis of BMMCs genes revealed a
network with 19 central nodes as major gene regulators including ERK, JNK, and p38 MAP kinases, insulin, Ca
2+ and STAT3.
Comparison between active versus inactive SLE identified 30 central nodes associated with immune response, protein
synthesis, and post-transcriptional modification. A high degree of identity between networks in active SLE and non-
Hodgkin’s lymphoma (NHL) patients was found, with overlapping central nodes including kinases (MAPK, ERK, JNK, PKC),
transcription factors (NF-kappaB, STAT3), and insulin. In validation studies, western blot analysis in splenic B cells from 5-
month-old NZB/NZW F1 lupus mice showed activation of STAT3, ITGB2, HSPB1, ERK, JNK, p38, and p32 kinases, and
downregulation of FOXO3 and VDR compared to normal C57Bl/6 mice.
Conclusions/Significance: Gene network analysis of lupus BMMCs identified central gene regulators implicated in disease
pathogenesis which could represent targets of novel therapies in human SLE. The high similarity between active SLE and
NHL networks provides a molecular basis for the reported association of the former with lymphoid malignancies.
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Introduction
Although gene profiling studies provide important information
for key molecules relevant to a disease, they are less informative of
protein-protein interactions, post-translational modifications and
regulation by targeted subcellular localization. In several diseases,
important proteins such as MAP kinases, are activated by
phosphorylation while their mRNA and protein levels remain
constant. To identify the molecular mechanisms by which these
genes lead to complex disease phenotypes, such as obesity,
diabetes, osteoarthritis, multiple sclerosis, juvenile rheumatoid
arthritis and other autoimmunse diseases [1–4], it is essential to
integrate genomic data and construct functional gene networks
that will be predictive of these diseases.
By the use of microarrays in the peripheral blood or bone marrow,
we and others have previously shown specific gene signatures that are
involved in SLE and correlate with disease activity [5–8]. Compared to
peripheral blood, bone marrow may be more informative in accessing
immune reactions in SLE patients [5]. In our study, BM gene analysis
differentiated SLE patients based on their disease activity and identified
genes involved in apoptosis [5]. Accelerated apoptosis and impaired
clearance of apoptotic cells due to the decreased phagocytic ability of
macrophages, monocytes and neutrophils have a pathogenic role in
SLE [9–11].
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13351In this study, we identified the signaling networks where these
genes are involved by integrating gene expression profiling data,
derived from bone marrow of lupus patients and healthy
individuals [5], using bioinformatic approaches. Identification of
the central nodes (also called hubs) in these networks could
uncover unique targets of novel therapies for lupus patients.
Results
Identification of gene network central nodes in SLE
patients
Differentially expressed genes between SLE patients and
controls were organized into an interactome network using
Ingenuity Pathway Analysis (IPA). The differentially expressed
genes derived from the microarray data constructed a gene
network with 19 central nodes (including JNK, ERK, p38, Insulin,
STAT3, FN1, Ca
2+)( Figure 1A). These nodes are major gene
regulators in the network as deletion of any of these nodes
pertubates or destroys the network. This complex gene network
consists of 4 major gene sub-networks (Figure 1B). The most
significant gene network (p=10
235) is involved in cellular growth
and has as central nodes the following molecules: BCL3, JNK,
insulin, p38 MAPK, MBP, PKC, NFkB, ERK, MAPK and CCR5
(Figure 1C). Among them, MBP, PKC, CCR5 were down-
regulated (green color) in SLE, BCL3 was up-regulated (red color),
while the remaining genes were not affected (white color)
(Figure 1C).
Identification of gene networks involved in disease
activity
We next constructed gene networks based on the microarray
analysis of active versus inactive SLE patients. Figure 2A shows
30 hubs (including ERK, STAT, AKT, PI3K, LYN, PDGF, FOS,
TP53) consisting of 9 gene sub-networks (Figure 2B). The most
significant gene network (p=10
250) consisted mainly of proteins
that were up-regulated in active patients (by our microarray
analysis); AKT, NF-kB, HSP90, proteosome, IER3 and HSPB1
emerged as central nodes (Figure 2C). The identification of these
proteins as central nodes supports their involvement in SLE
activity.
Correlation between lupus and other diseases on
genomic level
To detect any possible correlation between lupus and other
diseases at the genomic level, we compared the differentially
expressedgenesbetween SLE and controlsamplesandotherdisease
gene sets. Comparisons were made with the existing genomic data
provided by the software. SLE was highly associated with
neurological, renal, cardiovascular diseases and cancer (Table
S1). When comparisons involved only those genes differentially
expressed between SLE active and inactive patients, we found that
gene networks from patients with increased activity were related to
cancer, renal, infectious, and cardiovascular diseases (Table S2).
Because of the high correlation between active SLE networks
and cancer, we next sought to identify the types of cancer that
correlated highly with lupus. Comparison literature-mining gene
networks for the 18 most common types of cancer relative to lupus
gene network, revealed a high similarity between SLE gene
network derived from active SLE and non-Hodgkin’s lymphoma
(NHL) gene network. Specifically, we identified 23 hubs in the
NHL gene network (Figure S1A), among which seven (ERK,
JNK, MAPK, NFKB, PKC, STAT, insulin) were common with
the SLE gene network (Figure S1B).
Activation of kinase pathways in lupus mice
Bone marrow is a central lymphoid organ with a major role in
production, maturation and activation of B cells. To validate our
findings from the gene network analysis, we examined the
expression of several hubs identified from our analysis by
quantitative real-time PCR and western blot analysis in spleen B
cells obtained from C57Bl/6 and NZB/NZW F1 diseased mice.
This analysis revealed a distinct set of kinases activated in NZB/
NZW F1 mice. Specifically, ERK1/2, SAPK/JNK and p38
MAPK kinases were activated (phosphorylated) while their protein
levels were not altered (Figure 3A). We also found activation of
the AKT signaling pathway, which is involved in cellular survival
by inhibiting apoptotic processes. Specifically, the tumor suppres-
sor gene PTEN was down-regulated whereas AKT phosphoryla-
tion was enhanced (Figure 3B). Other gene network hubs that
were validated in NZB/NZW F1 spleen B cells included the
transcription factor FOXO3 and vitamin D receptor (VDR),
which were both downregulated at mRNA and protein level
(Figures 3C, D). In contrast, ITGB2 (encoding the b2 integrin
family), HSPB1 (co-chaperone that binds to and regulates the
chaperone Hsp70), and STAT3 were upregulated. Western blot
analysis further showed increased phosphorylation of STAT3
(pSTAT3) in lupus B cells (Figure 3D).
Discussion
SLE is a complex disease affecting multiple organs character-
ized by variable course and periods of remissions and flares.
Although its etiology is not established, many pathogenic pathways
are thought to contribute to tissue injury. Several of the central
node molecules identified in our analysis have been implicated in
lupus pathogenesis. Comparison between patients and controls
predicted involvement of pathways related to both survival (ERK,
JNK, MAPK, P38 MAPK, and BCL3) and immune-reactions
(STAT3, NFKB, CCR5, MBP) in the development of SLE. The
high similarity between active SLE and NHL gene networks is
provocative in view of data documenting a correlation of SLE with
malignancies, especially NHL where a 3 to 4-fold increased risk is
observed [12,13]. Our findings suggest that MAPK and
inflammatory pathways link SLE with NHL at the molecular level.
Several human and murine studies that are not included in the
IPA Knowledge BaseH have demonstrated activation of multiple
kinases and transcription factors including the MAPKs MEK1/
ERK1/2, p38, the PI3K/AKT/mTOR axis, the NF-kB and
multiple Bcl-2 family members, and the Jak/STAT pathway [14–
19]. We confirmed activation of these kinases in B cells from
NZB/NZW F1 lupus mice, predicted to play a central pathogenic
role based on the gene network analysis. Activation of MAPKs,
PI3K/AKT and NF-kB occurs downstream of receptors with a
key role in recognition of antigens, immunoglobulins and nucleic
acids, all of which have been linked to the aberrant immune
response in lupus.
Our analysis also revealed calcium and STAT proteins as
central regulators in SLE gene network [20]. An emerging aspect
of the Jak/STAT signaling pathway biology is the cross-talk with
ITAM-containing receptors and adaptor molecules and the
cross-regulation by calcium-dependent signaling pathways.
Increased levels and activation of STAT1 has been reported in
the spleen, lymph nodes, and kidneys of MRL/lpr and NZB/
NZW F1 lupus mice [21]. STAT1 phosphorylation in target
organs was potentiated by type I interferons, which have a clearly
defined pathogenic role in SLE. Moreover, pharmacologic
inhibition of the calcium–dependent kinase CaMKII in vivo
prevented IFNa-induced STAT1 phosphorylation and induction
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NZB/NZW F1 lupus mice. Increased phosphorylation of STAT5
and STAT3 have been reported in B cells of the congenic
B6.Sle1ab
z and B6Sle1
z.Sle3
z lupus mice [21,22], and Harada et al.
[23] have demonstrated increased STAT3 mRNA levels in T
cells from SLE patients, associated with enhanced chemokine-
induced cell migration. The presence of insulin as central node in
SLE, confirms previous findings of changes in bioenergetics
during T cell activation and systemic inflammation in humans.
Insulin is required to support the elevated energetic and
biosynthetic demands of growth proliferation and effector
function [1,24].
Comparison of active versus inactive SLE microarray data
identified a total of 30 central nodes; in contrast comparison of
SLE versus healthy controls revealed only 19 central nodes. This
suggests that additional signaling pathways are deregulated in
active SLE. Involvement of AKT, NF-kB, HSP90, proteosome,
IER3 and HSPB1 as central nodes in the gene network of active
patients highlights their importance in SLE since the PI3K/AKT/
mTOR signaling pathway plays an important role in the
differentiation of peripheral B cells and in T cell homeostasis.
Over-expression of PI3K in T cells results in the development of
lymphoproliferative and autoimmune disorders. Conversely,
inhibition of PI3Kc in the MRL/lpr mouse model of lupus
reduced glomerulonephritis and prolonged life span [22,25].
The strength of the gene network strategy was further
documented by our validation experiments in lupus mice. Proteins
such as ERK, JNK and p38 MAPK kinases, were not detected by
microarray analysis as their mRNA levels were not altered.
Nonetheless, they were predicted to be central molecules
implicated in SLE pathogenesis based on integration of microarray
data on differentially expressed genes and construction of gene
networks. These data imply that several kinase pathways are
activated in lupus and suggest the potential therapeutic use of
kinase inhibitors in these patients.
Our validation analysis in NZB/NZW F1 B cells demonstrated
decreased mRNA and protein levels of VDR, which mediates the
pleiotropic immunological effects of vitamin D. Of note, several
SLE cohorts have low vitamin D levels, and addition of vitamin D
to PBMCs results in a significant reduction of polyclonal and anti-
dsDNA antibody production by SLE B cells through direct
inhibition of their differentiation [26]. In accordance with a
previous study in lupus-prone (BXSB, MRL/lpr) mice [27], we
also observed decreased expression of FOXO3, a transcription
factor that participates in negative regulation of Th1 responses.
Importantly, our human SLE gene network analysis and murine
validation studies revealed – for the first time – a possible
pathogenic role for: a) HSPB1, a co-chaperone that regulates the
chaperone Hsp70 and is involved in stress-induced cell migration
[28], and b) ITGB2, encoding the b2 integrin family, that was
reported to protect against development of autoimmune diabetes
in NOD/LtJ mice [29].
In summary, our analysis has revealed that lupus pathogenesis is
contingent upon the activation of gene networks in which the
pivotal nodes could be targets for development of new therapeutic
strategies [30]. Gene network analysis based on gene profiling data
may represent a powerful method to predict key gene regulators
and identify shared pathways among distinct categories of complex
diseases.
Materials and Methods
Patients
Gene expression (cDNA) microarray data were obtained from
bone marrow mononuclear cells (BMMCs) from 20 SLE patients.
Control sample included 7 healthy individuals and 3 patients with
osteoarthritis (non-inflammatory knee arthritis). All patients met
the 1982 American College of Rheumatology revised criteria for
the classification of SLE [31] and were recruited from the
Rheumatology Department, University Hospital of Heraklion
(Greece). To capture patients with higher disease activity, we used
a SLE Disease Activity Index (SLEDAI) score cut-off of $8; 11
patients were classified as active (5 patients had active proliferative
and/or membranous nephritis while another 5 patients had active
neuropsychiatric lupus with psychosis, major depression, myelitis,
and polyneuropathy) and 9 as inactive. A written consent was
obtained by all patients and healthy individuals and the study was
approved by the Ethics Committee of the University Hospital of
Heraklion.
Generation of cDNA microarrays
Experimental procedures are described in detail elsewhere [5].
Briefly, BMMCs were isolated by Ficoll-Histopaque (Sigma-
Aldrich, St. Louis, MO) density-gradient centrifugation of bone
marrow aspirates, and were immediately placed in Trizol
(Invitrogen, Carlsbad, CA, USA) and processed for RNA
extraction using the RNeasy kit (Qiagen). cDNA was synthesized
from 2 mg of RNA using Omniscript reverse transcriptase (Qiagen)
with direct incorporation of Cy3-dUTP. Labeled cDNA was
purified using Montage 96-well vacuum system (Millipore). cDNA
was added to hybridization buffer containing human CoT-1 DNA
(0.5 mg/ml), yeast tRNA (0.2 mg/ml), and poly(dA)40–60 (0.4 mg/
ml).
Microarray production was performed using a commercially
available genome-scale oligonucleotide library containing gene-
specific 70-mer oligonucleotides and representing 21,329 human
genes. The library includes 16 replicate spots of 12 random
negative controls that are designed to have no significant
homology to known human DNA sequences (Qiagen). Oligonu-
cleotides were spotted onto Corning UltraGAPS
TM amino-silane
coated slides and were covalently fixed to the surface of the glass
using 300 mJ of ultraviolet radiation at a 254 nm wavelength.
Microarrays were scanned using a simultaneous dual-color, 48-
slide scanner (Agilent Technologies).
Figure 1. Pathway analysis of bone marrow genes in SLE patiens versus controls. (A) A gene network of 19 central nodes was constructed
by using the differentially expressed genes in the bone marrow of SLE patients and controls, as described in Materials and Methods. Deletion of any of
these nodes pertubates or destroys the gene network. Genes are colored according to gene expression value; red gene symbols indicate up-
regulation and green gene symbols indicate down-regulation. Nodes are displayed using various shapes that represent the functional class of the
gene product. Edges with dashed lines show indirect interaction, while a continuous line represents direct interactions (see explanatory inset). (B)
Four gene sub-networks are related to nucleic and amino acid metabolism, cell growth and protein synthesis. A dataset containing the differentially
expressed genes, called the focus molecules, between SLE and controls was overlaid onto a global molecular network developed from information
contained in the Ingenuity Pathways Knowledge Base. Networks of these focus molecules were then algorithmically generated based on their
connectivity. The composite score of the networks represents the negative log of the p-value for the likelihood that network molecules would be
found together by chance. Accordingly, a higher score indicates greater statistical significance that molecules depicted in the network are
interconnected. (C) The most significant gene network is involved in cellular growth.
doi:10.1371/journal.pone.0013351.g001
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The R/Bioconductor Package ‘‘Affy’’ was used to perform gene
expression quantile normalization to adjust the marginal distribu-
tion of each sample. Genes with average background adjusted
fluorescent intensity value .50 across all arrays were retained in
the analysis. The variance across genes was also calculated, and
genes with a variance below the median value were considered
unlikely to be differentially expressed (DE) and were not retained
for further analysis. DE genes between two classes were identified
through an unpaired Student’s t test. A 10% false discovery rate p-
value multiplicity adjustment was used. The false discovery rate is
the proportion of the list of genes claimed to be DE that are false
positives. Only statistically significant DE genes with greater than a
2-fold change in expression between groups were retained.
Gene Network Analysis
Gene networks were constructed and important hubs were
identified using Ingenuity Pathway Analysis (IPA; Ingenuity
Systems, Mountain View, CA) based on DE genes between SLE
patients and healthy individuals (n=102 genes) and between active
and inactive SLE (n=245 genes) [5]. IPA is a robust and expertly
curated database containing updated information on more than
20,000 mammalian genes and proteins, 1.4 million biological
interactions, and 100 canonical pathways incorporating over 6,000
discreet gene concepts. This information is integrated with relevant
databases such as Entrez-Gene and Gene Ontology. The
experimental data sets were used to query the IPA and to compose
a set of interactive networks taking into consideration canonical
pathways, the relevant biological interactions, and the cellular and
disease processes. Pathways of highly interconnected genes were
identified by statistical likelihood using the following equation:
Score~{log10 1{
X f{1
i~0
CG ,i ðÞ CN {G,s{i ðÞ
CN ,s ðÞ
 !
Where N is the number of genes in the network of which G are
central node genes, for a pathway of s genes of which f are central
node genes. C(n,k) is the binomial coefficient. We considered
statistically significant networks those with a score greater than 5 (p
value ,10
25).
Gene Ontology Analysis
Gene Ontology Analysis was performed using IPA. Specifically,
we performed gene ontology analysis by using the lupus gene
signatures (derived from comparisons between lupus versus control
samples and also between lupus active versus inactive samples) and
identified the correlation and statistical significance between lupus
and any other disease. Gene sets were collected from previously
published papers and included 1406 genes for various metabolic
disorders [32], 494 genes for atherosclerosis [33], and 855 genes
for malignant disorders [34–37]. We considered as statistical
significant the correlations with a p value ,0.05.
Comparison between Lupus and Cancer Gene Networks
To correlate lupus with other diseases in the gene network level,
we compared lupus gene network derived from our data with
cancer (breast, lung, thyroid, gastric, colon, liver, pancreas,
prostate, melanomas, Hodgkin lymphoma, non-Hodgkin’s lym-
phoma, acute myeloid leukemia, chronic lymphocytic leukemia,
acute lymphoblastic leukemia, chronic myelogenous leukemia)
gene networks derived from the Ingenuity Program. The level of
statistical significant (p value) was set to 10
25 to allow for multiple
comparisons in gene networks.
Protein Expression Analysis
Five-month old female NZB/NZW F1 mice were used. Mice
were intercrossed and maintained in a temperature-controlled
germ-free facility (Harvard Medical School, USA) on a 12-h light/
dark cycle, and fed by standard chow diet and water ad libitum.
Animal studies were performed according to National Institutes of
Health (USA) guidelines following protocols approved by the
Institutional Animal Care and Use Committee of Boston University
(MA, USA). Spleen B cells were isolated by magnetic separation
using CD19 microbeads (Miltenyi Biotec, Germany). Cells were
lysed in RIPA buffer containing 50 mM Tris-HCl, pH 7.2,
150 mM sodium chloride, 1% NP-40, 12 mM sodium deoxycho-
late, 3 mM sodium dodecyl sulfate, 4 mM sodium azide, 0.57 mM
phenylmethysulfonyl fluoride and 10 mg/L complete protease
inhibitor coctail. Protein expression and phosphorylation levels of
ERK1/2, SAPK/JNK, p38 MAPK and AKT proteins were
evaluated by western blot analysis. The antibodies used for protein
detection were: phospho-ERK1/2 (cat. no 4377, Cell Signaling),
ERK1/2 (cat no. 4695, Cell Signaling), phospho-SAPK/JNK (cat
no. 4668, Cell Signaling), SAPK-JNK (cat no. 9252, Cell Signaling),
phospho-p38 MAPK (cat no. 4631, Cell Signaling), p38 MAPK (cat
no. 9212, Cell Signaling), PTEN (cat no. sc-56205, Santa Cruz
Biotechnology Inc), phospho-AKT S473 (cat no. sc-101629, Santa
Cruz Biotechnology Inc), AKT (cat no. ab8805, Abcam Inc),
FOXO3 (cat no. ab47409, Abcam), ITGB2 (cat no. ab86457,
Abcam), HSPB1 (cat no. ab2790, Abcam), VDR (cat no. ab3508,
Abcam), STAT3 (cat no. 9139, Cell Signaling), phospho-STAT3
(cat no. 9138, Cell Signaling), b-actin (cat no. ab8227, Abcam Inc).
ELISA assay for assessing AKT S473 phosphorylation
status
The phosphorylation status of Akt S473 was assessed by ELISA
assay following the manufacturer instructions (cat.no SUV887,
R&D Systems). This immunoassay employs a two-site sandwich
ELISA to quantitate Akt phosphorylated at S473 in cell lysates.
Spleen B cells were isolated by magnetic separation using CD19
microbeads (Miltenyi Biotec, Germany) and then were lysed on ice
for 15 min and centrifuged at 2,000 g for 5 minutes. Supernatants
were transferred into clean tubes and incubated with phospho-Akt
antibody for 2 h at room temperature. After 3 washes the
supernatants were incubated with streptavidin-HRP for 20
minutes at room temperature. The next step was to add 100 ml
substrate solution and incubate for 20 minutes at room
temperature followed by 50 ml of stop solution and then read at
450 nm within 30 minutes. Data represent the average of three
different samples derived from different mice.
mRNA Expression Analysis
Total RNA was extracted from spleen B cells by the Trizol
method followed by RNeasy columns purification. Equal amounts
Figure 2. Network analysis of differentially expressed genes in the bone marrow of active versus inactive SLE patients. (A) Gene
network analysis in the bone marrow of active versus inactive patients with SLE revealed 30 central nodes, and (B) 9 gene sub-networks that illustrate
major functions of these pathways. (C) The most significant network consists of proteins that are up-regulated in active patients. See Figure 1 legend
for more details on gene network analysis and description.
doi:10.1371/journal.pone.0013351.g002
Gene Networks in SLE
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13351Figure 3. Validation of gene network results in NZB/NZW F1 lupus mice. (A) Western blot analysis in isolated spleen B cells from lupus NZB/
NZW F1 mice revealed activation of several kinases identified in gene network analysis. ERK1/2, SAPK/JNK, and p38 MAPK kinases were
phosphorylated while their total protein levels were not altered in NZB/NZW F1 compared to control C57Bl/6 (B6) mice. (B) Activation of AKT
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6 mice were reverse-transcribed to cDNA, which was subjected to
SYBR Green based real-time polymerase chain reaction analysis.
The following sets of primers were used: FOXO3: 59-CAAC-
CAAGGAAATGCTCCTC-39 (forward) and 59-ACAAAGT-
GAGCCGTTTGTCC -39 (reverse), ITGB2: 59-ACCAGCCCA-
GAGGTGACTGT-39 (forward) and 59-CTGCTCCTGGATG-
CACTCTGT -39 (reverse), HSPB1: 59-GCCGCACCAGCCTT-
CAGC-39 (forward) and 59-CACGCCTTCCTTGGTCTT-
CACT-39 (reverse), VDR: 59-CTGACCCTGGAGACTTT-
GAC-39 (forward) and 59-TTCCTCTGCACTTCCTCATC-39
(reverse), STAT3: 59-AAGGAGACATGCAGGATCTGA -39
(forward) and 59-TTCTGCACGTACTCCATTGC-39 (reverse),
b-actin: 59-GAGACCTTCAACACCCCAGC-39 (forward) and
59-ATGTCACGCACGATTTCCC-39 (reverse). The amplifica-
tion efficiencies of the target and the reference genes were similar
as indicated by the standard curves, and the following formula
was used: fold difference =2
2(DCtA–DCtB), where Ct is the cycle
threshold.
Supporting Information
Table S1 Differentially expressed genes between SLE patients
and controls highly correlate with other diseases on genomic level.
Found at: doi:10.1371/journal.pone.0013351.s001 (0.03 MB
DOC)
Table S2 Differentially expressed genes between active and
inactive SLE patients correlate with other diseases on genomic
level.
Found at: doi:10.1371/journal.pone.0013351.s002 (0.03 MB
DOC)
Figure S1 Gene network analysis identifies a high degree of
identity between active SLE and non-Hodgkin’s lymphoma
patients. (A) Gene networks in patients with non-Hodgkin’s
lymphoma (NHL). (B) Overlapping central nodes between SLE
and NHL gene networks.
Found at: doi:10.1371/journal.pone.0013351.s003 (2.26 MB TIF)
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